Earl Martin
Family Medicine · Tomball, TXNPI 1013998384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,058 and has fallen 89.7% since, to $109 in 2025.
Across 211 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$488
- Novo Nordisk$412
- AbbVie$276
- Novartis$240
- Hikma Pharmaceuticals USA$210
- Lilly USA, LLC$198
- plus $2K from 23 others
Across 9,103 payments — averaging $3315.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$16M
- Modernatx, Inc.$8.5M
- Valneva Austria GmbH$1.5M
- Bavarian Nordic A/s$1.4M
- Seqirus USA Inc$800K
- Boehringer Ingelheim$635K
- plus $1.3M from 11 others
What the payments were for
- Food & beverage$3,30799%
- Education$271%
- Gifts$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $488 |
| Novo Nordisk | 26 | $412 |
| AbbVie(2 entities) | 16 | $276 |
| Novartis | 14 | $240 |
| Hikma Pharmaceuticals USA | 11 | $210 |
| Lilly USA, LLC | 12 | $198 |
| Boehringer Ingelheim | 7 | $146 |
| AstraZeneca | 10 | $143 |
| GSK | 8 | $138 |
| Aytu Biopharma, Inc. | 17 | $128 |
| Johnson & Johnson | 4 | $91 |
| Amarin Pharma, Inc. | 5 | $90 |
| Clarus Therapeutics Inc. | 8 | $86 |
| Pfizer | 6 | $80 |
| Radius Health, Inc. | 4 | $80 |
| Merck | 4 | $77 |
| IBSA Pharma Inc. | 4 | $57 |
| Antares Pharma, Inc. | 3 | $54 |
| Arbor Pharmaceuticals, Inc. | 4 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Acerus Pharmaceuticals Corporation | 3 | $46 |
| Abbott | 2 | $38 |
| Edwards Lifesciences | 1 | $37 |
| Bayer | 2 | $36 |
| Bausch Health US, LLC | 2 | $31 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
$3,354 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Tomball
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.